Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 2:16 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 457–480 of 919 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Invasive Cancer Clear all

Conditions: Bladder Cancer
Interventions: Intravenous ascorbic acid/vitamin C; Drug
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 2
States / cities: Iowa City, Iowa • Kansas City, Kansas

Conditions: Metastatic Breast Cancer, Leptomeningeal Disease
Interventions: High-dose Methotrexate (8 gm/m2; HD-MTX); Drug
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2027
U.S. locations: 3
States / cities: Baltimore, Maryland • St Louis, Missouri • Winston-Salem, North Carolina

Conditions: Cancer
Interventions: counseling intervention, educational intervention, psychosocial assessment and care, quality-of-life assessment; Other · Procedure
Lead sponsor: Dartmouth-Hitchcock Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 329 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2013
U.S. locations: 2
States / cities: Lebanon, New Hampshire • White River Junction, Vermont

Conditions: Triple Negative Breast Cancer
Interventions: Sacituzumab govitecan-hziy (SG), Pembrolizumab, Capecitabine; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 1,514 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2031
U.S. locations: 188
States / cities: Birmingham, Alabama • Huntsville, Alabama • Glendale, Arizona + 158 more

Conditions: Invasive Breast Cancer, Metastatic Breast Cancer, HR-Positive Breast Cancer, HER2-negative Breast Cancer
Interventions: Pembrolizumab, Sacituzumab Govitecan; Drug
Lead sponsor: Ana C Garrido-Castro, MD; Other
Eligibility: 18 Years and older
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 8
States / cities: Atlanta, Georgia • Chicago, Illinois • Boston, Massachusetts + 5 more

Conditions: Non-muscle-invasive Bladder Cancer
Interventions: PLZ4-coated paclitaxel-loaded micelles (PPM); Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Breast Cancer
Interventions: Axillary Reverse Mapping; Procedure
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Muscle-Invasive Bladder Carcinoma, Bladder Cancer Stage II, Bladder Cancer Stage III, Bladder Cancer Stage IV
Interventions: Surveys; Other
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Bladder Cancer, Urinary Bladder Neoplasms
Interventions: MK-3120; Biological
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 4
States / cities: Bakersfield, California • New Brunswick, New Jersey • Myrtle Beach, South Carolina + 1 more

Conditions: Barrett Esophagus, Esophageal Adenocarcinoma
Interventions: Sponge Capsule; Device
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 90 Years
Enrollment: 1,526 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2025
U.S. locations: 8
States / cities: Scottsdale, Arizona • Jacksonville, Florida • Austin, Minnesota + 5 more

Conditions: Carcinoma, Squamous Cell of Head and Neck, HPV Positive Oropharyngeal Squamous Cell Carcinoma, Hypopharyngeal Cancer, Early Invasive Cervical Squamous Cell Carcinoma, Carcinoma of Larynx, Cancer of Nasopharynx
Interventions: BKM120, Cisplatin, Intensity-modulated radiotherapy (IMRT); Drug · Radiation
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2022
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Bladder Cancer
Interventions: Intervention, Control; Other
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 18 Years and older
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2021
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Bladder Cancer
Interventions: Nivolumab; Drug
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 2
States / cities: Tampa, Florida • Salt Lake City, Utah

Conditions: Bladder Cancer
Interventions: PF-07225570, sasanlimab; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 2
States / cities: New York, New York

Conditions: Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm
Interventions: Biospecimen Collection, Electronic Health Record Review, Interview, Survey Administration, Wearable Biosensor Patch; Procedure · Other · Device
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Duarte, California

Conditions: Breast Cancer Invasive, Prostate Cancer
Interventions: Audiovisual Intervention- Radiation Therapy Education, ASTRO Radiation Therapy for Breast or Prostate Cancer Brochure, Audiovisual Intervention- Cancer Clinical Trials Education, NCI Taking Part in Cancer Research Studies Brochure; Other
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older
Enrollment: 194 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 2
States / cities: Miami Beach, Florida • New York, New York

Conditions: Breast Ductal Carcinoma In Situ, Invasive Breast Carcinoma, Stage II Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7, Synchronous Bilateral Breast Carcinoma
Interventions: Health Education Program, Weight Loss Intervention; Other
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older · Female only
Enrollment: 3,177 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2030
U.S. locations: 1464
States / cities: Daphne, Alabama • Mobile, Alabama • Anchorage, Alaska + 921 more

Conditions: Muscle Invasive Bladder Cancer, High Risk Urothelial Carcinoma of the Upper Urinary Tracts
Interventions: single arm dose dense MVAC; Drug
Lead sponsor: Fox Chase Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 2
States / cities: Philadelphia, Pennsylvania

Conditions: Breast Cancer
Interventions: Brachytherapy APBI, 3D-CRT (photon) APBI, Proton APBI; Radiation
Lead sponsor: Mayo Clinic; Other
Eligibility: 50 Years and older · Female only
Enrollment: 170 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2022
U.S. locations: 3
States / cities: Phoenix, Arizona • Jacksonville, Florida • Rochester, Minnesota

Conditions: Breast Ductal Carcinoma In Situ, COVID-19 Infection, Hereditary Breast Carcinoma, Invasive Breast Carcinoma
Interventions: Questionnaire Administration; Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2028
U.S. locations: 4
States / cities: Conroe, Texas • Houston, Texas • League City, Texas + 1 more

Conditions: Urinary Bladder Cancer
Interventions: gemcitabine + docetaxel; Drug
Lead sponsor: University of Arizona; Other
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Locally Advanced or Metastatic Urothelial Cell Carcinoma, Urinary Bladder Disease, Urological Diseases
Interventions: Vofatamab, Docetaxel, Placebo; Drug
Lead sponsor: Rainier Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 11
States / cities: Gilbert, Arizona • Goodyear, Arizona • Duarte, California + 8 more

Conditions: Liver Cancer
Interventions: Not listed
Lead sponsor: Pathfinder Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Non-Muscle Invasive Bladder Carcinoma
Interventions: BCG Solution, Best Practice, Cystoscopy, Home Health Encounter, Survey Administration; Biological · Other · Procedure
Lead sponsor: Ohio State University Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2028
U.S. locations: 1
States / cities: Columbus, Ohio

Search by objective public record fields.

Intravenous Ascorbate Plus Gemcitabine/Carboplatin: A Novel and Cost-Effective Alternative With Evident Efficacy in Patients With Muscle Invasive Bladder Cancer

Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis

Early Intervention vs. Standard Palliative Care in Improving End-of-Life Care in Advanced Cancer Patients

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)

Sacituzumab Govitecan +/- Pembrolizumab In HR+ / HER2 - MBC

A Phase I Intravesical PPM Therapy for NMIBC

Axillary Reverse Mapping for Invasive Carcinoma of the Breast

Addressing Barriers to Palliative Care Use in Bladder Cancer

A Clinical Study of MK-3120 in People With Bladder Cancer (MK-3120-003)

Minimally Invasive Molecular Approaches for the Diagnosis of Barrett's Esophagus and Esophageal Adenocarcinoma

Phase Ib Study of BKM120 With Cisplatin and XRT in High Risk Locally Advanced Squamous Cell Cancer of Head and Neck

Surveillance for Low and Low-Intermediate Risk Non-muscle Invasive Bladder Cancer: A Pilot Study

Adjuvant Nivolumab Following Chemo-Radiation in Localized Muscle-Invasive Bladder Cancer

PF-07225570 Alone or in Combination With an Anti-PD-1 Antibody in Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)

A Wearable Biosensor Patch for Non-Invasive Monitoring for Patients Undergoing Abdominal or Chest Surgery

AVI Didactic Experience for Latinx Patient Treatment Adherence and Non-English Speaker Trial Enrollment Study in Rad Onc

Breast Cancer WEight Loss Study (BWEL Study)

Dose Dense MVAC for Muscle Invasive Bladder Cancer

A Study of Accelerated 3 Fraction Photon,Proton or Brachytherapy for Early Invasive and Noninvasive Breast Ca

Impact of COVID-19 Pandemic on Out-of-Pocket Costs, Lost Wages, and Unemployment in Patients With Breast Cancer Undergoing Breast Surgery

Intravesical Gem/Doce in Patients With NMIBC

Dose Escalation, Expansion Study of Vofatamab (B-701) in Treatment of Locally Advanced or Metastatic Urothelial Cell Carcinoma

Evaluation of a Minimally Invasive Image-Guided Surgery System for Hepatic Ablation Procedures

Home-Based Outpatient Model for BCG Delivery to Reduce Undue Burden on Patients Undergoing Treatment for Non-Muscle Invasive Bladder Carcinoma